Skip to main content

ESTUDIO DE LAS CARNITINAS PALMITOILTRANSFERASAS EN HIPOTALAMO COMO POTENCIALES DIANAS PARA EL CONTROL DE LA INGESTA Y TRATAMIENTO DE LA OBESIDAD

SAF2014-52223-C2-1-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Rapamycin negatively impacts insulin signaling, glucose uptake and uncoupling protein-1 in brown adipocytes

  • García-Casarrubios, Ester
  • Arroba, Ana I.
  • Pescador, Nuria
  • García, Laura
  • Cadenas, Susana
  • Carvalho, Eugenia
  • Obregón, María Jesús
  • Valverde, Ángela M.
New onset diabetes after transplantation (NODAT) is a metabolic disorder that affects 40% of patients on immunosuppressive agent (IA) treatment, such as rapamycin (also known as sirolimus). IAs negatively modulate insulin action in peripheral tissues including skeletal muscle, liver and white fat. However, the effects of IAs on insulin sensitivity and thermogenesis in brown adipose tissue (BAT) have not been investigated. We have analyzed the impact of rapamycin on insulin signaling, thermogenic gene-expression and mitochondrial respiration in BAT. Treatment of brown adipocytes with rapamycin for 16 h significantly decreased insulin receptor substrate 1 (IRS1) protein expression and insulin-mediated protein kinase B (Akt) phosphorylation. Consequently, both insulin-induced glucose transporter 4 (GLUT4) translocation to the plasma membrane and glucose uptake were decreased. Early activation of the N-terminal Janus activated kinase (JNK) was also observed, thereby increasing IRS1 Ser 307 phosphorylation. These effects of rapamycin on insulin signaling in brown adipocytes were partly prevented by a JNK inhibitor. In vivo treatment of rats with rapamycin for three weeks abolished insulin-mediated Akt phosphorylation in BAT. Rapamycin also inhibited norepinephrine (NE)-induced lipolysis, the expression of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and uncoupling protein (UCP)-1 in brown adipocytes. Importantly, basal mitochondrial respiration, proton leak and maximal respiratory capacity were significantly decreased in brown adipocytes treated with rapamycin. In conclusion, we demonstrate, for the first time the important role of brown adipocytes as target cells of rapamycin, suggesting that insulin resistance in BAT might play a major role in NODAT development., This work was supported by Ministerio de Economía y Competitividad: (SAF2015-65267-R to AMV, SAF2012-32491 to MJO, SAF2013-45887-R to LH, and SAF2014-52223-C2-1-R to DS) that were cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea [FEDER], Spain, Instituto de Salud Carlos III (FIS PI15-00448 to SC and INFLAMES PIE14/00045 to AMV), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem, ISCIII, Spain) to AMV, Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBERobn-Grant CB06/03/0001) to DS and S2010/BMD-2423 (Comunidad de Madrid, Spain) to AMV and MJO and S2010/BMD-2402 to SC and 2014SGR465 (Generalitat de Catalunya, Spain) to DS. CdM was supported by the Albert Reynold Grant travel fellowship from the European Foundation for the Study of Diabetes. EC and FR were funded by FEDER through the Operational Programme Competitiveness Factors - COMPETE and by FCT - Foundation for Science and TechnologyPTDC/SAU-OSM/104124/2008 and strategic project UID/NEU/04539/2013., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Carnitine palmitoyltransferase 1 increases lipolysis, UCP1 protein expression and mitochondrial activity in brown adipocytes

  • Calderón‐Domínguez, María
  • García-Casarrubios, Ester
  • Obregón, María Jesús
  • Valverde, Ángela M.
  • Herrero, Laura
This is an open access article distributed under the terms of the Creative Commons Attribution License.-- et al., The discovery of active brown adipose tissue (BAT) in adult humans and the fact that it is reduced in obese and diabetic patients have put a spotlight on this tissue as a key player in obesity-induced metabolic disorders. BAT regulates energy expenditure through thermogenesis; therefore, harnessing its thermogenic fat-burning power is an attractive therapeutic approach. We aimed to enhance BAT thermogenesis by increasing its fatty acid oxidation (FAO) rate. Thus, we expressed carnitine palmitoyltransferase 1AM (CPT1AM), a permanently active mutant form of CPT1A (the rate-limiting enzyme in FAO), in a rat brown adipocyte (rBA) cell line through adenoviral infection. We found that CPT1AM-expressing rBA have increased FAO, lipolysis, UCP1 protein levels and mitochondrial activity. Additionally, enhanced FAO reduced the palmitate-induced increase in triglyceride content and the expression of obese and inflammatory markers. Thus, CPT1AM-expressing rBA had enhanced fat-burning capacity and improved lipid-induced derangements. This indicates that CPT1AM-mediated increase in brown adipocytes FAO may be a new approach to the treatment of obesity-induced disorders., This work was supported by the Ministry of Spain - MINECO (SAF2013-45887-R to LH, SAF2014-52223-C2-1-R to DS and SAF-2015-65267-R to AMV that were cofunded by the Fondos Europeos de Desarrollo Regional de la Unión Europea [FEDER], SAF2012-32491 to MJO, SAF2013-40987R to AZ, and a doctoral fellowship to JFM), the Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 to DS), the Centro de Investigación Biomédica en red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), the Generalitat de Catalunya (2014SGR465 to DS, and 2014SGR48 to AZ), the Comunidad de Madrid (S2010/BMD-2423 to MJO and AMV), INTERREG IV-B-SUDOE-FEDER (DIOMED, SOE1/P1/E178) to AZ, and the European Foundation for the Study of Diabetes (EFSD)/Janssen-Rising Star and L’Oréal-UNESCO “For Women in Science” research fellowships to LH. AZ is a recipient of ICREA-Academia (Generalitat de Catalunya) and MW is a recipient of the Ciência sem Fronteiras-CNPq fellowship (237976/2012-9)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ceramides and mitochondrial fatty acid oxidation in obesity

  • Fucho, Raquel
  • Casals, Núria
  • Serra, Dolors
  • Herrero, Laura
Obesity is an epidemic, complex disease that is characterized by increased glucose, lipids, and low-grade inflammation in the circulation, among other factors. It creates the perfect scenario for the production of ceramide, the building block of the sphingolipid family of lipids, which is involved in metabolic disorders such as obesity, diabetes, and cardiovascular disease. In addition, obesity causes a decrease in fatty acid oxidation (FAO), which contributes to lipid accumulation within the cells, conferringmore susceptibility to cell dysfunction. C16:0 ceramide, a specific ceramide species, has been identified recently as the principal mediator of obesity-derived insulin resistance, impaired fatty acid oxidation, and hepatic steatosis. In this review, we have sought to cover the importance of the ceramide species and their metabolism, the main ceramide signaling pathways in obesity, and the link between C16:0 ceramide, FAO, and obesity., This work was supported by the Ministry of Spain (MINECO) Grants SAF2013-45887-R (to L.H.), SAF2014-52223-C2-1-R (to D.S.), and SAF2014-52223-C2-2-R (to N.C.), and cofunded by the Fondos Europeos de Desarrollo Regional (FEDER); and by Centro de Investigacion Biom ´ edica en Red de Fisiopatolog ´ ´ıa de la Obesidad y la Nutricion (CIBEROBN) Grant CB06/03/0001 ´ (to D.S.); Government of Catalonia Grant 2014SGR465 (to D.S.); Marato TV3 Foundation (to D.S., N.C.); and the ´ European Foundation for the Study of Diabetes (EFSD)/ Janssen-Rising Star and L’Or´eal-UNESCO “For Women in Science” research fellowships (to L.H.), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ghrelin causes a decline in GABA release by reducing fatty acid oxidation in cortex

  • Mir, Joan Francesc
  • Zagmutt, Sebastián
  • Lichtenstein, Mathieu
  • García-Villoria, Judit
  • Weber, Minéia
  • Gracia, Ana
  • Fabriàs, Gemma
  • Casas, Josefina
  • López, Miguel
  • Casals, Núria
  • Ribes, Antònia
  • Suñol, Cristina
  • Herrero, Laura
  • Serra, Dolors
Lipid metabolism, specifically fatty acid oxidation (FAO) mediated by carnitine palmitoyltransferase (CPT) 1A, has been described to be an important actor of ghrelin action in hypothalamus. However, it is not known whether CPT1A and FAO mediate the effect of ghrelin on the cortex. Here, we show that ghrelin produces a differential effect on CPT1 activity and γ-aminobutyric acid (GABA) metabolism in the hypothalamus and cortex of mice. In the hypothalamus, ghrelin enhances CPT1A activity while GABA transaminase (GABAT) activity, a key enzyme in GABA shunt metabolism, is unaltered. However, in cortex CPT1A activity and GABAT activity are reduced after ghrelin treatment. Furthermore, in primary cortical neurons, ghrelin reduces GABA release through a CPT1A reduction. By using CPT1A floxed mice, we have observed that genetic ablation of CPT1A recapitulates the effect of ghrelin on GABA release in cortical neurons, inducing reductions in mitochondrial oxygen consumption, cell content of citrate and α-ketoglutarate, and GABA shunt enzyme activity. Taken together, these observations indicate that ghrelin-induced changes in CPT1A activity modulate mitochondrial function, yielding changes in GABA metabolism. This evidence suggests that the action of ghrelin on GABA release is region specific within the brain, providing a basis for differential effects of ghrelin in the central nervous system., This work was supported by the Ministry of Spain (MINECO) (SAF2015-71026-R and BFU2015-70454-REDT/ Adipoplast to ML, SAF2013-45887-R to LH, SAF2014-52223-C2-1-R to DS, and SAF2014-52223-C2-2-R to NC, cofunded by the European Regional Development Fund [ERDF]), the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 to DS), the Government of Catalonia (2014SGR465 to DS), the Fundació La Marató de TV3 (201627-30 to DS), the Xunta de Galicia (2015-CP079 to ML) and the European Community’s Seventh Framework Programme (FP7/2007- 2013) under grant agreement no. 281854 – the ObERStress project to ML., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet‐induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula
  • Casas, Josefina
  • Salvador, Javier
  • Rodríguez, Amaia
  • Alonso, Sergio
  • Sebastián, David
  • Soler‐Vázquez, M. Carmen
  • Montironi, Carla
  • Recalde, Sandra
  • Fucho, Raquel
  • Calderón‐Domínguez, María
  • Mir, Joan Francesc
  • Bartrons, Ramón
  • Escolà-Gil, Joan Carles
  • Sánchez‐Infantes, David
  • Zorzano, Antonio
  • Llorente-Cortés, Vicenta
  • Casals, Núria
  • Valentí, Víctor
  • Frühbeck, Gema
  • Herrero, Laura
  • Serra, Dolors
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high‐fat diet (HFD)‐induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno‐associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD‐induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9‐hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD‐induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans., We thank Gloria González‐Aseguinolaza for kindly supplying the EalbAATp promoter. Financial support statement: This study was supported by the Ministry of Spain (MINECO) (SAF2014‐52223‐C2‐1‐R to DS, SAF2017‐83813‐C3‐1‐R to DS and LH, SAF2017‐82813‐C3‐3R to NC co‐financed by the European Regional Development Fund [ERDF], a doctoral fellowship to JFM, and a Juan de la Cierva—Incorporación research fellowship [IJCI‐2016‐28313] to PM and DS), the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (CB06/03/0001 to DS), the Government of Catalonia (2014SGR465 to DS), Instituto de Salud Carlos III (FISPI18/01584 to VL‐C, FIS‐PI17/00412 to RB, FIS PI18/01484 to SA and FIS17/01455 to DS‐I, Miguel Servet Fund CP15/00106 to DS‐I and Rio Hortega grant (CM19/00039) to CM) and co‐financed by the European Regional Development Fund (ERDF), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) to JC‐EG, the Fundació La Marató de TV3 (201627‐30 to DS and 201627‐31 to NC), the European Foundation for the Study of Diabetes (EFSD)/Lilly and EFSD/Janssen‐Rising Star and L'Oréal‐UNESCO “For Women in Science” research fellowships to LH, a doctoral fellowship from the Ciência sem Fronteiras‐CNPq (237976/2012‐9) to MW. Figure 4F was created with BioRender.com., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

  • Benitez-Amaro, Aleyda
  • Revuelta-López, Elena
  • Bornachea, Olga
  • Cedó, Lídia
  • Vea, Ángela
  • Herrero, Laura
  • Roglans, Núria
  • Soler-Botija, Carolina
  • Gonzalo-Calvo, David de
  • Nasarre, Laura
  • Camino-López, Sandra
  • García, Eduardo
  • Mató, Eugènia
  • Blanco-Vaca, Francisco
  • Bayés Genís, Antoni
  • Sebastián, David
  • Laguna, Joan Carles
  • Serra, Dolors
  • Llorente-Cortés, Vicenta
Background Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to explore the potential mechanisms involved. Methods We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes exclusively in cardiomyocytes to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). Findings Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1−/−) have a normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Glucose intolerance protection was linked to higher hepatic fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. cm-Lrp1−/− mice showed ANP signaling activation that was linked to increased fatty acid (FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic protection in cm-Lrp1−/− mice. Conclusions These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism., This work was funded by FIS PI14/01729 and FIS PI18/01584 (to VLl-C), FIS16/00139 (to JCE-G) grants from Instituto Salud Carlos III, co-financed by the European Fund for Regional Development (E.F.R.D.) and by the Ministry of Spain-MINECO (SAF2014-52223-C2-1-R to DS, co-financed by the European Fund for Regional Development (E.F.R.D.). Support was received from Ministerio de Economía y Competitividad to DdG-C (IJCI-2016-29393), Agència de Gestió d'Ajuts Universitaris i de Recerca Grant FI to ERL (FI-DGR 2013/00014), Fundació MARATÓ TV3 Project 201521-10 (to VLl-C) and Project 87/C/2016 to DS. CIBER Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM; CB07/08/0016 (FBV, JCE-G, LC); CB07/08/0017 (AZ), CIBER Fisiopatología de la Obesidad y la Nutrición (CIBEROBN; CB06/03/0001 (DS, LH); CB06/03/0017 (JCL, NR)) and CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/1100403) (DdG-C, VLl-, CS, ERL and AB-G) are Instituto de Salud Carlos III (ISCIII) projects., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CPT1C promotes human mesenchymal stem cells survival under glucose deprivation through the modulation of autophagy

  • Roa Mansergas, Xavier
  • Fadó Andrés, Rut
  • Atari Abouassi, Maher
  • Mir, Joan Francesc
  • Muley Vilamú, Helena
  • Serra, Dolors
  • Casals i Farré, Núria
Tis work was supported by the Ministry of Spain (SAF2014-52223-C2-1-R and SAF2017-82813-C3-3R and granted to DS, and SAF2014-52223-C2-2-R and SAF2017-82813-C3-3R granted to NC), all grants co-funded by Fondos Europeos de Desarrollo Regional de la Unión Europea –FEDER-), the Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 granted to DS), the Generalitat de Catalunya (2014SGR465 granted to DS and NC), Fundació La Marató de TV3 (201627.30.31 granted to DS and NC), CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII. Te funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Dr. Antonio Zorzano and Dr. David Sebastian for assistance with the extracellular fux analysis., Human mesenchymal stem cells (hMSCs) are widely used in regenerative medicine. In some applications, they must survive under low nutrient conditions engendered by avascularity. Strategies to improve hMSCs survival may be of high relevance in tissue engineering. Carnitine palmitoyltransferase 1 C (CPT1C) is a pseudoenzyme exclusively expressed in neurons and cancer cells. In the present study, we show that CPT1C is also expressed in hMSCs and protects them against glucose starvation, glycolysis inhibition, and oxygen/glucose deprivation. CPT1C overexpression in hMSCs did not increase fatty acid oxidation capacity, indicating that the role of CPT1C in these cells is different from that described in tumor cells. The increased survival of CPT1C-overexpressing hMSCs observed during glucose deficiency was found to be the result of autophagy enhancement, leading to a greater number of lipid droplets and increased intracellular ATP levels. In fact, inhibition of autophagy or lipolysis was observed to completely block the protective effects of CPT1C. Our results indicate that CPT1C-mediated autophagy enhancement in glucose deprivation conditions allows a greater availability of lipids to be used as fuel substrate for ATP generation, revealing a new role of CPT1C in stem cell adaptation to low nutrient environments., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Increased infammation, oxidative stress and mitochondrial respiration in brown adipose tissue from obese mice

  • Alcalá, Martín
  • Calderón-Domínguez, María
  • Bustos, Eduviges
  • Ramos, Pilar
  • Casals i Farré, Núria
  • Serra, Dolors
  • Viana, Marta
  • Herrero Rodríguez, Laura
Tis work was supported by the Ministry of Spain (MINECO) (SAF2013-45887-R to LH, SAF2014-56671R to PR, SAF2014-52223-C2-1-R to DS, and SAF2014-52223-C2-2-R to NC, cofunded by the European Regional Development Fund [ERDF]), the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 to DS), the Government of Catalonia (2014SGR465 to DS), and the Fundació La Marató de TV3 to DS. We acknowledge A. Zorzano and D. Sebastián (IRB, Barcelona, Spain) for assistance with the Seahorse., Obesity is associated with severe metabolic diseases such as type 2 diabetes, insulin resistance, cardiovascular disease and some forms of cancer. The pathophysiology of obesity-induced metabolic diseases has been strongly related to white adipose tissue (WAT) dysfunction through several mechanisms such as fibrosis, apoptosis, inflammation, ER and oxidative stress. However, little is known of whether these processes are also present in brown adipose tissue (BAT) during obesity, and the potential consequences on mitochondrial activity. Here we characterized the BAT of obese and hyperglycemic mice treated with a high-fat diet (HFD) for 20 weeks. The hypertrophic BAT from obese mice showed no signs of fibrosis nor apoptosis, but higher levels of inflammation, ER stress, ROS generation and antioxidant enzyme activity than the lean counterparts. The response was attenuated compared with obesity-induced WAT derangements, which suggests that BAT is more resistant to the obesity-induced insult. In fact, mitochondrial respiration in BAT from obese mice was enhanced, with a 2-fold increase in basal oxygen consumption, through the upregulation of complex III of the electron transport chain and UCP1. Altogether, our results show that obesity is accompanied by an increase in BAT mitochondrial activity, inflammation and oxidative damage., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet‐induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula
  • Casas, Josefina
  • Salvador, Javier
  • Rodríguez, Amaia
  • Alonso, Sergio
  • Sebastián, David
  • Soler-Vázquez, M. Carmen
  • Montironi, Carla
  • Recalde, Sandra
  • Fucho, Raquel
  • Calderón-Domínguez, María
  • Mir, Joan Francesc
  • Bartrons, Ramon
  • Escola-Gil, Joan Carles
  • Sánchez-Infantes, David
  • Zorzano, Antonio
  • Llorente-Cortes, Vicenta
  • Casals i Farré, Núria
  • Valentí, Víctor
  • Frühbeck, Gema
  • Herrero Rodríguez, Laura
  • Serra, Dolors
We thank Gloria González-Aseguinolaza for kindly supplying the EalbAATp promoter. Financial support statement: This study was supported by the Ministry of Spain (MINECO) (SAF2014-52223-C2-1-R to DS, SAF2017-83813-C3-1-R to DS and LH, SAF2017-82813-C3-3R to NC co-financed by the European Regional Development Fund [ERDF], a doctoral fellowship to JFM, and a Juan de la Cierva—Incorporación research fellowship [IJCI-2016-28313] to PM and DS), the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (CB06/03/0001 to DS), the Government of Catalonia (2014SGR465 to DS), Instituto de Salud Carlos III (FISPI18/01584 to VL-C, FIS-PI17/00412 to RB, FIS PI18/01484 to SA and FIS17/01455 to DS-I, Miguel Servet Fund CP15/00106 to DS-I and Rio Hortega grant (CM19/00039) to CM) and co-financed by the European Regional Development Fund (ERDF), Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) to JC-EG, the Fundació La Marató de TV3 (201627-30 to DS and 201627-31 to NC), the European Foundation for the Study of Diabetes (EFSD)/Lilly and EFSD/Janssen-Rising Star and L'Oréal-UNESCO “For Women in Science” research fellowships to LH, a doctoral fellowship from the Ciência sem Fronteiras-CNPq (237976/2012-9) to MW. Figure 4F was created with BioRender.com., The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high‐fat diet (HFD)‐induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno‐associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD‐induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9‐hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD‐induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sensing of nutrients by CPT1C regulates late endosome/lysosome anterograde transport and axon growth

  • Palomo Guerrero, Marta
  • Fadó Andrés, Rut
  • Casas, Maria
  • Pérez-Montero, Marta
  • Baena, Miguel
  • Helmer, Patrick O.
  • Domínguez, José Luis
  • Roig, Aina
  • Serra, Dolors
  • Hayen, Heiko
  • Stenmark, Harald
  • Raiborg, Camilla
  • Casals i Farré, Núria
We are very grateful to Eva M Wenzel for her help in the settings of live imaging experiments and critical discussion. This work was supported by the Ministry of Spain (MINECO) (Grants SAF2014- 52223-C2-1-R to DS, SAF2017-83813-C3-1-R to DS, SAF2014-52223-C2-2-R to NC, and SAF2017- 82813-C3-3R to NC, cofunded by the European Regional Development Fund [ERDF]), the Centro de Investigacion Biomedica en Red Fisiopatologı´a de la Obesidad y la Nutricion (CIBEROBN) (Grant CB06/03/0001 to DS), the Generalitat de Catalunya (2014SGR465 to DS and NC), Fundacio´ La Marato´ de TV3 (Grant 87/C/2016 to DS and NC). POH thanks the Fonds der Chemischen Industrie (FCI, Frankfurt am Main, Germany) for a PhD scholarship. The authors declare no competing financial interests., Anterograde transport of late endosomes or lysosomes (LE/Lys) is crucial for proper axon growth. However, the role of energetic nutrients has been poorly explored. Malonyl-CoA is a precursor of fatty acids, and its intracellular levels highly fluctuate depending on glucose availability or the energy sensor AMP-activated protein kinase (AMPK). We demonstrate in HeLa cells that carnitine palmitoyltransferase 1C (CPT1C) senses malonyl-CoA and enhances LE/Lys anterograde transport by interacting with the endoplasmic reticulum protein protrudin and facilitating the transfer of Kinesin-1 from protrudin to LE/Lys. In cultured mouse cortical neurons, glucose deprivation, pharmacological activation of AMPK or inhibition of malonyl-CoA synthesis decreases LE/Lys abundance at the axon terminal, and shortens axon length in a CPT1C-dependent manner. These results identify CPT1C as a new regulator of anterograde LE/Lys transport in response to malonyl-CoA changes, and give insight into how axon growth is controlled by nutrients., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

CPT1C in the ventromedial nucleus of the hypothalamus is necessary for brown fat thermogenesis activation in obesity

  • Rodríguez-Rodríguez, Rosalía
  • Miralpeix Monclús, Cristina
  • Fosch, Anna
  • Pozo Ariza, Macarena
  • Calderón-Domínguez, María
  • Perpinyà, Xavier
  • Vellvehí, Miquel
  • López, Miguel
  • Herrero Rodríguez, Laura
  • Serra, Dolors
  • Casals i Farré, Núria
This work was supported by the Ministerio de Economía, Industria y Competitividad (MINECO), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (Grants SAF2014-52223-C2-2-R to NC, SAF2017-83813-C3-3-R to NC and RR-R, SAF2014-52223-C2-1-R to DS, SAF2017-83813-C3-1-R to DS and LH, SAF2015-71026-R to ML, TEC2014-51903-R to MV and XP, and Ramón y Cajal RYC-2010-07434 to XP), the Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN) (Grant CB06/03/0001 to DS), the Generalitat de Catalunya (2014SGR465 to DS and NC, 2017SGR1384 to MV and XP), Fundació La Marató de TV3 (Grant 87/C/2016 to DS and NC), and by Projectes de Recerca per a investigadors novells (2015) to RR-R. AF is the recipient of a fellowship from the Agència de Gestió d’Ajuts Universitaris i de la Recerca (AGAUR) in Catalonia., Objective: Carnitine palmitoyltransferase 1C (CPT1C) is implicated in central regulation of energy homeostasis. Our aim was to investigate whether CPT1C in the ventromedial nucleus of the hypothalamus (VMH) is involved in the activation of brown adipose tissue (BAT) thermogenesis in the early stages of diet-induced obesity. Methods: CPT1C KO and wild type (WT) mice were exposed to short-term high-fat (HF) diet feeding or to intracerebroventricular leptin administration and BAT thermogenesis activation was evaluated. Body weight, adiposity, food intake, and leptinemia were also assayed. Results: Under 7 days of HF diet, WT mice showed a maximum activation peak of BAT thermogenesis that counteracted obesity development, whereas this activation was impaired in CPT1C KO mice. KO animals evidenced higher body weight, adiposity, hyperleptinemia, ER stress, and disrupted hypothalamic leptin signaling. Leptin-induced BAT thermogenesis was abolished in KO mice. These results indicate an earlier onset leptin resistance in CPT1C KO mice. Since AMPK in the VMH is crucial in the regulation of BAT thermogenesis, we analyzed if CPT1C was a downstream factor of this pathway. Genetic inactivation of AMPK within the VMH was unable to induce BAT thermogenesis and body weight loss in KO mice, indicating that CPT1C is likely downstream AMPK in the central mechanism modulating thermogenesis within the VMH. Quite opposite, the expression of CPT1C in the VMH restored the phenotype. Conclusion: CPT1C is necessary for the activation of BAT thermogenesis driven by leptin, HF diet exposure, and AMPK inhibition within the VMH. This study underscores the importance of CPT1C in the activation of BAT thermogenesis to counteract diet-induced obesity., info:eu-repo/semantics/acceptedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low-density lipoprotein receptor-related protein 1 deficiency in cardiomyocytes reduces susceptibility to insulin resistance and obesity

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Bornachea, Olga
  • Cedó, Lídia|||0000-0003-4354-3411
  • Vea Badenes, Angela|||0000-0001-7856-6635
  • Herrero, Laura|||0000-0003-4244-4673
  • Roglans, Nuria
  • Soler-Botija, Carolina|||0000-0002-4584-9134
  • Gonzalo Calvo, David de|||0000-0003-2240-3532
  • Nasarre, Laura
  • Camino-López, Sandra|||0000-0002-2737-4892
  • García, Eduardo
  • Mato, Eugènia|||0000-0001-8121-9335
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sebastian, David
  • Laguna, Joan Carles|||0000-0002-2357-1186
  • Serra, Dolors|||0000-0002-4936-4206
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipemia, LRP1 is upregulated in the heart. Our aim was to evaluate the impact of cardiomyocyte LRP1 deficiency on high fat diet (HFD)-induced cardiac and metabolic alterations, and to explore the potential mechanisms involved. Methods: We used TnT-iCre transgenic mice with thoroughly tested suitability to delete genes exclusively in cardiomyocytes to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). Findings: Mice with Lrp1-deficient cardiomyocytes (cm-Lrp1-/-) have a normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Glucose intolerance protection was linked to higher hepatic fatty acid oxidation (FAO), lower liver steatosis and increased whole-body energy expenditure. Proteomic studies of the heart revealed decreased levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which was parallel to higher ANP circulating levels. cm-Lrp1-/- mice showed ANP signalingactivation that was linked to increased fatty acid (FA) uptake and increased AMPK/ ACC phosphorylation in the liver. Natriuretic peptide receptor A (NPR-A) antagonist completely abolished ANP signaling and metabolic protection in cm-Lrp1-/- mice. Conclusions: These results indicate that an ANP-dependent axis controlled by cardiac LRP1 levels modulates AMPK activity in the liver, energy homeostasis and whole-body metabolism.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

  • Weber, Minéia
  • Mera, Paula|||0000-0001-8941-4637
  • Casas, Josefina|||0000-0002-7926-5209
  • Salvador, Javier
  • Rodríguez, Amaia|||0000-0002-2180-461X
  • Alonso Muñoz, Sergio|||0000-0002-3989-8757
  • Sebastián, David|||0000-0002-7260-3869
  • Soler Vázquez, M. Carmen|||0000-0003-1430-5617
  • Montironi, Carla|||0000-0002-1453-2193
  • Recalde, Sandra|||0000-0002-6174-0649
  • Fucho, Raquel|||0000-0002-1774-9099
  • Calderon-Dominguez, María|||0000-0003-1797-3450
  • Mir, Joan Francesc|||0000-0001-8501-0969
  • Bartrons, Ramon|||0000-0001-9349-5847
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sánchez-Infantes, David|||0000-0001-6086-7501
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Casals, Nuria|||0000-0002-6719-4300
  • Valentí, Victor|||0000-0002-7074-2849
  • Frühbeck, Gema|||0000-0002-8305-7154
  • Herrero, Laura|||0000-0003-4244-4673
  • Serra, Dolors|||0000-0002-4936-4206
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the global obesity pandemic but at present there are no approved therapies. Here, we aimed to revert high-fat diet (HFD)-induced obesity and NAFLD in mice by enhancing liver fatty acid oxidation (FAO). Moreover, we searched for potential new lipid biomarkers for monitoring liver steatosis in humans. We used adeno-associated virus (AAV) to deliver a permanently active mutant form of human carnitine palmitoyltransferase 1A (hCPT1AM), the key enzyme in FAO, in the liver of a mouse model of HFD-induced obesity and NAFLD. Expression of hCPT1AM enhanced hepatic FAO and autophagy, reduced liver steatosis, and improved glucose homeostasis. Lipidomic analysis in mice and humans before and after therapeutic interventions, such as hepatic AAV9-hCPT1AM administration and RYGB surgery, respectively, led to the identification of specific triacylglyceride (TAG) specie (C50:1) as a potential biomarker to monitor NAFFLD disease. To sum up, here we show for the first time that liver hCPT1AM gene therapy in a mouse model of established obesity, diabetes, and NAFLD can reduce HFD-induced derangements. Moreover, our study highlights TAG (C50:1) as a potential noninvasive biomarker that might be useful to monitor NAFLD in mice and humans.